Products
News
Newsletter
Subscribe to our newsletter:
products | SX-8G IP-Star® Automated System
Description
SX-8G IP-Star® Automated System increases your epigenetic lab’s productivity, efficiency and experimental reproducibility. Optimizing assay conditions for ChIP, MeDIP, MBD capture, etc., is a challenging but necessary process: numerous factors, including the amount of starting material, type of cells, level of enrichment of chromatin or DNA, and the number of samples must each be optimized. For each factor, it is also necessary to consider the additional requirements of downstream analysis methods. Manual optimization is time-consuming, and prone to variability introduced by manual pipetting steps. Further, if assay parameters are optimized individually, rather than collectively, the resulting “optimized” protocol will not take into account the complex interactions that can exist between the experimental factors.
The SX-8G IP-Star processes sheared chromatin or DNA to deliver purified DNA ready for qPCR, amplification, microarray and sequencing (e.g. Illumina™) analysis. The system is capable of processing up to 16 samples per cycle in ChIP, MeDIP and MBD assays. It performs fully-automated liquid handling, magnetic separation, and incubation, significantly accelerating the optimization process, while also enhancing assay quality and robustness -- all within the rapid timeframe researchers require. The flexibility in the IP-Star’s easy-to-use, open software enables users to create unique protocols to address specific needs. The system’s flexibility and elimination of error-prone manual steps lets users develop protocols that produce consistent, results across different operators, labs, and networks, achieving an unparalleled level of data reproducibility. For example, it allows researchers to repeat experiments on different days - or even different months or years - and achieve the same results every time.
Transfer your ChIP, MeDIP or MBD assay to the SX-8G IP-Star System and discover the benefits of automation: data you can trust, giving you the ability to focus on what’s important: answering the scientific questions.
| SX-8G IP-Star® Automated System | UH-001-0001 | 1 unit | CONTACT US | |
Major benefits
Ideal protocol optimization
• Eliminates variation introduced by tools
• Eliminates variation introduced by operator
• Optimizes multiple parameters simultaneously
• Accounts for complex interactions between experimental factors
Time saving
• Improves time to result
• Dramatically reduce hands-on time
• Achieves flexible scheduling of experiments
Improves assay reproducibility
• Increases consistency with automated assay processing
• Achieves robust performance with validated reagents
Reduces contamination risk
Articles
AutoMeDIP-seq: A high-throughput, whole genome, DNA methylation assay
PML-RARa/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
1. Automated immunoprecipitation of methylated DNA (MeDIP)
Automated immunoprecipitation of methylated DNA (MeDIP) using the Diagenode IP star is currently applied to several large scale cancer methylome projects some of them under the coordination of the International Cancer Genome Consortium at the Centre National de Génotypage (Evry, France). Automated MeDIP has successfully been coupled to promoter and CpG island tiling arrays as well as second generation sequencing. The automation of the immunoprecipitation has been shown to significantly increase the signal to noise ratio permitting a more rapid and reliable identification of differentially methylated candidate genes as assessed by high resolution quantitative pyrosequencing.
Dr Jörg Tost Centre National de Génotypage, Evry, France
Click here for more information
2. Automating whole-genome DNA methylation analyses
To automate the hands-on aspect of Methylated DNA Immunoprecipitation (MeDIP) - ‘Auto MeDIP’ & ‘Auto ChIP’ - Diagenode recently introduced a robotic liquid handler. We are currently using this machine to perform a series of custom assays with qPCR, microarrays and, ultimately, Illumina Solexa 2nd-generation sequencing. The Auto MeDIP workflow qualitatively distinguishes between methylated and unmethylated fragments. Future work: we aim test the Auto MeDIP workflow with Illumina sequencing using both control DNA and, as a proof-of-principle, experimental samples. These experiments will help fine-tune the methylation-scoring algorithms for use in future studies.
Dr Stephan Beck University College London London, WC1E 6BT, United Kingdom
Contact Person: Lee Butcher
Click here for more information
3. MethylCap-sequencing (Methyl binding domain - sequencing)
DNA methylation is the most stable epigenetic mark that is strongly associated with cancer. Genome-wide mapping of DNA methylation associated with human cancers provides a readout of their cancer epigenomes. The general expection is that catalogues of the differentially methylated regions will be of high diagnostic and/or prognostic value. Most studies performed thus far have been limited to proximal promoters and CpG islands. It is possible that genomic regions outside of promoters and CpG islands are also targets for differential methylation in a ‘cancer-type’ specific manner. A bottleneck in the genome-wide analysis of DNA methylation has been the lack of methods amenable for genome-scale analysis. Here we present a strategy based on capturing of methylated DNA fragments using an MBD protein (MethylCap), followed by deep sequencing that allows to interrogate the entire genome. The use of automated MethylCap guarentees high reproducibility and high-throughput in generating whole-genome DNA methylation profiles of human (cancer) genomes.
Project start: April 2009 (still in progress)
Dr Henk Stunnenberg Nijmegen Center for Molecular Life Sciences
Nijmegen, The Netherlands
Click here for more information
